Literature DB >> 10602743

Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia.

R A Peleman1, V Van De Velde, P R Germonpré, C Fleurinck, M T Rosseel, R A Pauwels.   

Abstract

The penetration of trovafloxacin (TVA), 200 mg once daily, into the airways of 17 patients with severe pneumonia was studied. The mean (standard deviations are given in parentheses) steady-state TVA concentrations, 2 h after the last intake, were 3.1 (0.3) mg/liter in induced sputum (n = 8), 3.2 (1.1) mg/liter in bronchial secretions (n = 9), 3.2 (0.9) mg/liter in bronchoalveolar lavage fluid (n = 10), and 4.9 (1.4) mg/liter in epithelial lining fluid (n = 11).

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10602743      PMCID： PMC89648          DOI： 10.1128/AAC.44.1.178-180.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.

Authors:  P C Fuchs; A L Barry; S D Brown; D L Sewell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

2.  Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy.

Authors:  J M Andrews; D Honeybourne; N P Brenwald; D Bannerjee; M Iredale; B Cunningham; R Wise
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

3.  Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.

Authors:  J G Bartlett; R F Breiman; L A Mandell; T M File
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

Review 4.  Methods of examining induced sputum: do differences matter?

Authors:  J C Kips; R A Peleman; R A Pauwels
Journal:  Eur Respir J       Date:  1998-03       Impact factor: 16.671

5.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

Authors:  S I Rennard; G Basset; D Lecossier; K M O'Donnell; P Pinkston; P G Martin; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1986-02

6.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 7.  Trovafloxacin: a new fluoroquinolone.

Authors:  A A Alghasham; M C Nahata
Journal:  Ann Pharmacother       Date:  1999-01       Impact factor: 3.154

8.  In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors:  B B Gooding; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.

Authors:  T K Ling; E Y Liu; A F Cheng
Journal:  Chemotherapy       Date:  1999 Jan-Feb       Impact factor: 2.544

10.  Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography.

Authors:  R Teng; T G Tensfeldt; T E Liston; G Foulds
Journal:  J Chromatogr B Biomed Appl       Date:  1996-01-12
View more
  2 in total

Review 1.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

Review 2.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.